Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party

It is often difficult to continue treatment with hypomethylating agent(HMA) in clinical practice because of problems such as toxicities, poor economics, etc. We compared clinical outcomes of those patients who continued HMA and those who discontinued HMA because of other causes, and evaluated factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Da Jung, Lee, Ho Sup, Moon, Joon-Ho, Sohn, Sang Kyun, Kim, Hyeoung Joon, Cheong, June-Won, Jo, Deog-Yeon, Kim, Hawk, Lee, Hyewon, Bang, Soo-Mee, Lee, Won Sik, Park, Yong, Lee, Mark Hong, Lee, Jae Hoon, Bae, Sung Hwa, Kim, Min Kyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668053/
https://www.ncbi.nlm.nih.gov/pubmed/29108320
http://dx.doi.org/10.18632/oncotarget.18258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668053/
https://www.ncbi.nlm.nih.gov/pubmed/29108320
http://dx.doi.org/10.18632/oncotarget.18258

Ejemplares similares